Comment

Ask this question - if Australian decision-makers can disregard the human impact of delays in reimbursed access to health technologies, why should they be excused from considering the broader consequences?

“Melanie brings a unique perspective and proven leadership in public health policy, and we are thrilled to welcome her to our Executive Team at such a critical time for the sector,” said Medicines Australia CEO Liz de Somer.

The US FDA has announced a plan to replace animal testing in the development of monoclonal antibody therapies and other drugs with 'human-relevant' methods such as advanced computer simulations and human-based lab models.

Ann Maccarrone, community engagement and partnerships manager at ViiV Healthcare Australia, said, “We are honoured to support the five recipients of the 2024 PACG program, whose initiatives align with our mission to create meaningful and lasting impact for people living with HIV, and to leave no person living with HIV behind."

According to an update from the Pharmaceutical Benefits Advisory Committee, it recently received correspondence from Health Minister Mark Butler requesting its advice "on equitable access to medicines for treatment of obesity in Australia."

Doug Swan, the executive general manager of wholesale and pharmacy services at Wesfarmers Health, said, “By investing in technology like myAPI, we’re ensuring pharmacy owners have 24/7 access to critical products and essential information at their fingertips.

The implementation group should not feel constrained by the recommendations, but it's tough to imagine any Government agreeing to one change without a second. The industry's leadership would understand this and be prepared given the timing.

New Zealand's Pharmac will fund Novo Nordisk's long-acting insulin therapy RYZODEG (insulin degludec and insulin aspart) from 1 May under an agreement that could benefit around 13,000 people in year one.

During the 2022 election campaign, Prime Minister Anthony Albanese and Mr Butler were unequivocal about their commitment to newborns and their parents.

Australia's election is two weeks in, and we're having trouble engaging. How positional power and 'expertism' can be confused and the value of a transparent and open forum.

Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials.

In the latest episode of the TrailblAZers podcast, Pharmacy Guild national president Professor Trent Twomey says that with 6,000 pharmacy locations and 40,000 registered pharmacists, the opportunity for the government is to support them to do more.